key: cord-0751598-4yncdcqb authors: Vaidya, Gaurang; Czer, Lawrence SC.; Kobashigawa, Jon; Kittleson, Michelle; Patel, Jignesh; Chang, David; Kransdorf, Evan; Shikhare, Anuja; Tran, Hai; Vo, Ashley; Ammerman, Noriko; Huang, Edmund; Zabner, Rachel; Jordan, Stanley title: Successful treatment of severe COVID-19 pneumonia with clazakizumab in a heart transplant recipient: case report date: 2020-06-07 journal: Transplant Proc DOI: 10.1016/j.transproceed.2020.06.003 sha: ac7d98b2b45464bdff4e293ba2c3f6f708df1512 doc_id: 751598 cord_uid: 4yncdcqb Abstract Background Severe Acute Respiratory Syndrome caused by coronavirus 2 (SARS-CoV-2) is characterized by an overwhelming cytokine response. Various treatment strategies have been attempted. Methods and Results A 61-year-old male with heart transplantation in 2017 presented with fever, cough, and dyspnea, and confirmed positive for the SARS-CoV-2 disease (COVID-19). Laboratory tests showed significant elevations in C-reactive protein and interleukin-6 (IL-6). Echocardiogram showed LVEF 58% (with EF 57% 6 months prior). Given the lack of clear management guidelines, the patient was initially managed symptomatically. However, the patient subsequently had a rapid respiratory deterioration with worsening inflammatory markers on day 5 of admission. Tocilizumab (anti-IL-6R) was in low supply in the hospital. The patient was offered clazakizumab (anti-IL-6) for compassionate use. Patient received 25 mg intravenously x1 dose. Within 24 hours, he noted significant improvement in symptoms, oxygen requirements, radiological findings and inflammatory markers. There was a transient leukopenia which improved in 4 days. He was discharged home on day 11, with negative nasopharyngeal SARS-CoV-2 PCR as an outpatient on day 35, development of positive serum COVID-19 IgG antibody, and he continued to do well on day 60, with no heart-related symptoms. Conclusion Clazakizumab is a monoclonal antibody against human IL-6, which may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Although not yet FDA approved, it is being investigated for treatment of renal antibody-mediated rejection. Clinical trials of clazakizumab for treatment of COVID-19 are underway worldwide. Background: Severe Acute Respiratory Syndrome caused by coronavirus 2 (SARS-CoV-2) is characterized by an overwhelming cytokine response. Various treatment strategies have been attempted. Methods and Results: A 61-year-old male with heart transplantation in 2017 presented with fever, cough, and dyspnea, and confirmed positive for the SARS-CoV-2 disease . Laboratory tests showed significant elevations in C-reactive protein and interleukin-6 (IL-6). Echocardiogram showed LVEF 58% (with EF 57% 6 months prior). Given the lack of clear management guidelines, the patient was initially managed symptomatically. However, the patient subsequently had a rapid respiratory deterioration with worsening inflammatory markers on day 5 of admission. Tocilizumab (anti-IL-6R) was in low supply in the hospital. The patient was offered clazakizumab (anti-IL-6) for compassionate use. Patient received 25 mg intravenously x1 dose. Within 24 hours, he noted significant improvement in symptoms, oxygen requirements, radiological findings and inflammatory markers. There was a transient leukopenia which improved in 4 days. He was discharged home on day 11, with negative nasopharyngeal SARS-CoV-2 PCR as an outpatient on day 35, development of positive serum COVID-19 IgG antibody, and he continued to do well on day 60, with no heart-related symptoms. Conclusion: Clazakizumab is a monoclonal antibody against human IL-6, which may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Although not yet FDA approved, it is being investigated for treatment of renal antibody-mediated rejection. Clinical trials of clazakizumab for treatment of COVID-19 are underway worldwide. Severe acute respiratory syndrome caused by the novel coronavirus (SARS-CoV-2) is characterized by an overwhelming inflammatory state with massive dysregulation of cytokines, contributing to widespread organ damage. Inhibition of the cytokine pathway could theoretically stop this cascade and interleukin-6 (IL-6) is one such target. Data from the literature 1, 2 and from our own center (unpublished observations) indicate that IL-6 is the predominant cytokine seen with SARS-CoV-2 pneumonia and substantiates the use of therapies against IL-6 or IL-6 receptor to dampen the cytokine storm in these patients. The present case highlights the potential utility of clazakizumab as an IL-6 inhibitor in reducing respiratory morbidity of COVID-19 in a patient infected with SARS-CoV-2 after heart transplant (HTx). A 61-year-old male who had orthotopic HTx in May 2017 with normal postoperative graft function presented with 1 week of dyspnea on exertion and non-productive cough. He had a sick contact (his wife) who was later diagnosed with COVID-19. His medications included tacrolimus 4 mg each morning (qAM) and 3 mg each evening (qPM), and mycophenolate mofetil (MMF) 1000 mg twice a day (BID). He was also on chronic prednisone 5 mg daily for rheumatoid arthritis and lisinopril 10 mg daily for hypertension. The past medical history included diabetes mellitus and a remote history of bladder cancer in remission. On presentation, his temperature was 38 degrees C, heart rate 92 beats/min, blood pressure 130/93 mmHg. His oxygen saturation was 98% on room air. He had mild acute renal injury with serum creatinine 1.4 mg/dL. He had normal white blood cell (WBC) count of 4.8 x 10 3 cells/uL with a normal differential of 71% neutrophils, 18% lymphocytes, and 0.4% eosinophils. He had mild anemia (hemoglobin 12 g/dL) and mild thrombocytopenia (platelets 121 x 10 3 cells/uL). Liver function tests, serum troponin, serum glucose, electrocardiogram and echocardiogram (normal graft function with LVEF 58%; prior EF 57% 6 months before) were unremarkable. Chest X-ray showed new bilateral lung infiltrates consistent with pneumonia. SARS-CoV-2 polymerase chain reaction (PCR) testing done on admission through a nasopharyngeal swab was positive and a repeat test done the next day confirmed the results. Subsequent blood tests included elevated erythrocyte sedimentation rate (50 mm/hr, reference <20 mm/hr), C-reactive protein (CRP 133 mg/L, reference <5 mg/L), myoglobin (78 ng/mL, reference <72 ng/mL), ferritin (1172 ng/mL, reference <275 ng/mL), D-dimer (1.31 mcg/mL, reference <0.7 mcg/mL) and lactate dehydrogenase (257 U/L, reference <220 U/L). Serum tacrolimus level was 11.7 ng/mL (goal 5-10 ng/mL) while the extent of immunosuppression using the T-cell immune function (TCIF) assay (Cylex test) showed an ATP level 39 ng/mL (reference for low immune cell response <225 ng/mL, indicating over-immunosuppression). Given the initial clinical stability, he was initially managed by supportive measures. Tacrolimus dose was decreased to 2 mg qAM and 1 mg qPM, and MMF to 750 mg BID, to reduce over-immunosuppression. On day 5 of admission, he had worsening of oxygen saturation and rapid escalation of oxygen therapy to 7L through a face mask and there was a discussion regarding invasive ventilation. He was hypotensive at 96/67 mmHg and tachycardic (111 beats/min). Chest x-ray showed interval worsening of underlying pneumonia (figure 1A). His CRP increased to 158 mg/L, with an elevated IL-6 level of 34 pg/mL (reference <7 pg/mL). Given the patient's deteriorating condition and his immunosuppressed state, a multidisciplinary discussion took place involving the infectious disease, pulmonary, medicine, and heart transplant teams. A decision was made to treat with an IL-6 inhibitor. Tocilizumab was reserved in the hospital for intubated, critically ill patients. Compassionate use of clazakizumab (Vitaeris) was approved by the FDA after obtaining the patient's consent and Institutional Review Board (IRB) approval. Tuberculosis was ruled out. Cytomegalovirus PCR was negative. Subsequently, the patient received a one-time dose of clazakizumab 25 mg in 50 mL normal saline, given over 30 minutes. No immediate side effects were noted. On the following day, the patient noted significant symptomatic improvement and the oxygen requirement dropped to 2L/min by nasal cannula. CRP decreased to 139 mg/L and continued to decrease to 8 mg/L, six days after the clazakizumab dose. Serum ferritin levels dropped from peak of 1172 to 673 ng/mL. WBC count decreased to 2.9 x 10 3 cells/uL, following which MMF was discontinued and tacrolimus dose was reduced further to 1 mg BID. The serum tacrolimus levels predominantly remained within goal (5-10 ng/mL) for the rest of the hospital stay. He was continued on his home prednisone dose; no intravenous steroid dose was administered. WBC count subsequently increased to 4.5 x 10 3 cells/uL in 4 days, while no worsening was noted in the other cell counts. No other relevant abnormalities were noted in other blood tests; IL-6 levels were not repeated. His chest x-ray showed interval improvement in the parenchymal infiltrates (figure 1B) and he was discharged home on day 11 of admission with the above changes in his medications. The repeat nasopharyngeal SARS-CoV-2 PCR was negative as an outpatient on day 35, and the serum COVID-19 IgG antibody was positive, consistent with prior infection. The patient continued to do well as an outpatient at day 60, with no ongoing heart-related symptoms. Herein we report a case of an immunosuppressed HTx recipient with SARS-CoV-2 infection and manifestations of COVID-19. Given the sudden clinical deterioration and signs of overwhelming inflammation in the form of cytokine storm, he was treated with anti-interleukin-6 monoclonal antibody, clazakizumab. This was associated with a rapid and significant clinical recovery and an improvement in inflammatory markers within a few days without any untoward adverse event. The case highlights a possible treatment strategy for COVID-19 patients to aid resolution of pulmonary infiltrates in an immunocompromised transplant recipient. The syndrome of COVID-19 after infection with SARS-CoV-2 is characterized by an overwhelming inflammatory state with massive dysregulation of cytokines, called cytokine storm. Excessive cytokine production may trigger secondary hemophagocytic lymphohistiocytosis with widespread tissue and organ damage. Interleukin-6 is a pleiotropic cytokine within the cascade of host defense contributing to acute phase reaction, innate immune response activation and other defensive activities 3 . A pathologically excessive production of IL-6 can result in chronic inflammation, characteristic of multiple systemic inflammatory conditions 3 associated with severe infections, including the previous H1N1 influenza pandemic 4 . In an observational study of 69 COVID-19 patients, most patients had an elevated lactate dehydrogenase, CRP, ferritin and D-dimer 1 . In association with these, the study also noted an increase in the baseline IL-6 levels, especially in severe infections. The authors suggested a potential use of IL-6 as a biomarker and also a target for future treatment of the disease 1 . Consequently, an attempt has been made to identify a role for IL-6 inhibitors in the treatment of COVID-19 patients. Tocilizumab is a humanized monoclonal antibody against the human IL-6 receptor. Xu et al 5 reported 21 hospitalized COVID-19 patients treated with tocilizumab (400 mg single dose). The patients had significant improvement in their oxygen requirements the next day, associated with a drop in CRP levels. Including previously critically ill patients, 91% of patients were subsequently discharged home within the study period and no adverse events were reported. A multicenter randomized, double-blinded, placebo-controlled phase III clinical trial is currently underway to establish the safety and efficacy of tocilizumab in the treatment of severe COVID-19 pneumonia (NCT04320615) 6 . Clazakizumab is a humanized IgG1 monoclonal antibody directed against human IL-6 instead of the IL-6 receptor 7 . Clazakizumab's efficacy and safety have been reported in rheumatoid arthritis and are being studied in late antibody-mediated rejection of kidney allografts 7 . Randomized placebo-controlled studies examining the benefits of clazakizumab in prevention and treatment of SARS-CoV-2 pneumonia are now underway at Cedars-Sinai Medical Center and NYU Langone Medical Center (NCT04348500 & NCT04343989) 8, 9 . Due to the current lack of proven therapies and clear guidelines, various other options were also considered in our patient. Hydroxychloroquine was not used, given the possibility of cardiac toxicity, and lack of randomized trial results in COVID-19. Tocilizumab has been restricted in our medical center for use in critically ill patients only. Clazakizumab was available on a compassionate use basis and approved by the FDA and local IRB, following administration of which the patient had significant reduction in inflammatory markers, and was discharged within 6 days of therapy. The high tacrolimus level at presentation and low TCIF (Cylex) level suggested over-immunosuppression, which can be a risk factor for SARS-CoV-2 infection. Subsequently, the immunosuppression was reduced. Despite the continued immunosuppression, he was able to mount a strong cytokine response. It is possible that the reduction in immunosuppression may have contributed to the cytokine response. Previous reports suggest that clazakizumab is significantly more potent (3-120 times) in in-vitro and ex-vivo assays 10 when compared with tocilizumab. Shin et al 11 reported a trial comparing the IL-6 signaling inhibition among kidney transplant patients with chronic antibody mediated rejection treated with clazakizumab (n=8) or tocilizumab (n=11). The study noted a significant increase in soluble IL-6 receptor and IL-6 after tocilizumab therapy (p= 0.03) which may contribute to an increased risk of rejection following cessation of therapy. No such increase was noted with clazakizumab therapy (p=0.7). However, robust comparative data between these two agents is missing. Nevertheless, clazakizumab provides a viable alternative to tocilizumab, especially when tocilizumab is in short supply as is the case at many centers. Another concern with tocilizumab is the potential for high levels of circulating IL-6R, negating tocilizumab through early saturation of the monoclonal before inhibition of cellular signaling can be achieved 12 . This is often manifested as a slow or no decline in inflammatory markers (i.e., CRP). As a result, patients may need additional doses to achieve inhibition of the IL-6/IL-6R signaling pathway. This has been noted in patients with the capillary leak syndrome where additional doses of tocilizumab are required 12 hours post-initial dose to fully inhibit IL-6/IL-6R signaling 13 . In this regard, the distribution and volume of the ligand (IL-6) should be much easier to inhibit. Clazakizumab is a well-tolerated agent with adverse effects which are dose-dependent, including mild infections, injection-site reaction, increase in aminotransferase and cholesterol levels, decreased neutrophil and platelet counts, while serious and opportunistic infections, malignancies, and autoimmune disorders are uncommon (5-9% incidence) 7, 14 . No adverse effects were noted in the current patient. The patient had normal graft function through the infection and remains currently asymptomatic on outpatient follow up. With regard to the heart transplant program, because of the risk to both donors and recipients from SARS-CoV-2 and COVID-19 during this time (March to May 2020), only urgent (status 1, 2, or 3) recipients were transplanted, and both donors and recipients were tested for SARS-CoV-2 by nasopharyngeal swab or broncho-alveolar lavage prior to transplant. After mid-May 2020, all status designations (1 through 6) for recipients were considered for transplant, but testing for SARS-CoV-2 was continued for all donors and recipients prior to transplant. In conclusion, clazakizumab can be a safe and efficacious option for management of the cytokine storm characteristic of severe COVID-19 pneumonia, including transplant recipients. Further trials are underway to establish this hypothesis. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019 Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Anti-interleukin 6 receptor antibody treatment in rheumatic disease Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza A infection Effective treatment of severe COVID-19 patients with tocilizumab A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial A Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Anti-IL-6 Antibody Clazakizumab Is More Potent Than Tocilizumab In Blocking In Vitro and Ex Vivo IL-6-Induced Functions. Abstract Presented at the ACR/ARHP AnnualMeeting CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR) Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. • Severe Acute Respiratory Syndrome caused by coronavirus 2 (SARS-CoV-2) is characterized by an overwhelming cytokine response.• A 61-year-old male with heart transplantation in 2017 presented with fever, cough, and dyspnea, and confirmed positive for the SARS-CoV-2 disease (COVID-19). Laboratory tests showed significant elevations in C-reactive protein, interleukin-6 (IL-6), and other inflammatory markers. Echocardiogram showed normal LV function.• The patient received clazakizumab (anti-IL-6 monoclonal antibody) 25 mg as a single dose, with significant improvement in symptoms, oxygen requirements, radiological findings and inflammatory markers within 24 hours, and discharge to home on day 11.He had a negative nasopharyngeal SARS-CoV-2 PCR as an outpatient on day 35, developed a positive serum COVID-19 IgG antibody, and was continuing to do well clinically on day 60.• Clazakizumab is a monoclonal antibody against human IL-6, which may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19.